Evidence map›Paper›PMID 38327517›Full record

ReviewFrontiers in immunology2024

Therapeutic targets and potential delivery systems of melatonin in osteoarthritis.

Zhilin Xiong, Guoxuan Peng, Jin Deng, Miao Liu, Xu Ning, Yong Zhuang, Hua Yang, Hong Sun

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Zhilin XiongDepartment of Orthopaedics, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Guoxuan PengDepartment of Orthopaedics, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Jin DengDepartment of Emergence Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Miao LiuDepartment of Orthopaedics, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Xu NingDepartment of Orthopaedics, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Yong ZhuangDepartment of Orthopaedics, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Hua YangDepartment of Orthopaedics, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Hong SunDepartment of Orthopaedics, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Guiyang Medical University · CNAffiliated Hospital of Guizhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) is a highly prevalent age-related musculoskeletal disorder that typically results in chronic pain and disability. OA is a multifactorial disease, with increased oxidative stress, dysregulated inflammatory response, and impaired matrix metabolism contributing to its onset and progression. The neurohormone melatonin, primarily synthesized by the pineal gland, has emerged as a promising therapeutic agent for OA due to its potential to alleviate inflammation, oxidative stress, and chondrocyte death with minimal adverse effects. The present review provides a comprehensive summary of the current understanding regarding melatonin as a promising pharmaceutical agent for the treatment of OA, along with an exploration of various delivery systems that can be utilized for melatonin administration. These findings may provide novel therapeutic strategies and targets for inhibiting the advancement of OA.

Indexed as

MelatoninOsteoarthritisChondrocytesHumansInflammationOxidative StressMelatoninchondrocyte deathdelivery systemsinflammationmelatoninosteoarthritisoxidative stress

Identifiers

PMID38327517
PMCPMC10847247
OpenAlexW4391172400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.